Journal
JOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume 28, Issue 3, Pages 419-425Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2013.09.010
Keywords
Proliferative retinopathy; Macular edema; Vitrectomy; KEGG pathway; VEGF; IL-8; IL-6; HGF; EPO
Categories
Funding
- American Health Assistance Foundation
- National Health and Medical Research Council Centre for Clinical Research Excellence Translational Clinical Research
- Australian National Health and Medical Research Council Postgraduate Scholarship
- Pfizer Australia
Ask authors/readers for more resources
The aim of this study was to perform a systematic meta-analysis of biomarkers investigated with diabetic retinopathy (DR) in the vitreous, and to explore the molecular pathway interactions of these markers found to be consistently associated with DR. Relevant databases [PubMed and ISI web of science] were searched for all published articles investigating molecular biomarkers of the vitreous associated with DR. Based on set exclusion/inclusion criteria available data from studies with human vitreous samples were extracted and used for our meta-analysis. The interactions of significant biomarkers in DR were investigated via STRING and KEGG pathway analysis. Our meta-analysis of DR identifies eleven biomarkers as potential therapeutic candidates alternate to current anti-VEGF therapy. Four of these are deemed viable therapeutic targets for PDR; ET receptors (ET A and ET B), anti-PDGF-BB, blocking TGF-beta using cell therapy and PEDF. The identification of supplementary or synergistic therapeutic candidates to anti VEGF in the treatment of DR may aid in the development of future treatment trials. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available